180 related articles for article (PubMed ID: 29220734)
1. High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS.
Merienne C; Rousset M; Ducint D; Castaing N; Titier K; Molimard M; Bouchet S
J Pharm Biomed Anal; 2018 Feb; 150():112-120. PubMed ID: 29220734
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
[TBL] [Abstract][Full Text] [Related]
3. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Bouchet S; Chauzit E; Ducint D; Castaing N; Canal-Raffin M; Moore N; Titier K; Molimard M
Clin Chim Acta; 2011 May; 412(11-12):1060-7. PubMed ID: 21345336
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
8. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring.
Koller D; Vaitsekhovich V; Mba C; Steegmann JL; Zubiaur P; Abad-Santos F; Wojnicz A
Talanta; 2020 Feb; 208():120450. PubMed ID: 31816725
[TBL] [Abstract][Full Text] [Related]
9. An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.
Abdelhameed AS; Attwa MW; Kadi AA
Biomed Chromatogr; 2017 Feb; 31(2):. PubMed ID: 27450926
[TBL] [Abstract][Full Text] [Related]
10. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
[TBL] [Abstract][Full Text] [Related]
11. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
van Erp NP; de Wit D; Guchelaar HJ; Gelderblom H; Hessing TJ; Hartigh Jd
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():33-43. PubMed ID: 24013127
[TBL] [Abstract][Full Text] [Related]
12. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Götze L; Hegele A; Metzelder SK; Renz H; Nockher WA
Clin Chim Acta; 2012 Jan; 413(1-2):143-9. PubMed ID: 21945732
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
[TBL] [Abstract][Full Text] [Related]
14. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
Couchman L; Birch M; Ireland R; Corrigan A; Wickramasinghe S; Josephs D; Spicer J; Flanagan RJ
Anal Bioanal Chem; 2012 Jun; 403(6):1685-95. PubMed ID: 22526649
[TBL] [Abstract][Full Text] [Related]
15. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry.
Ni MW; Zhou J; Li H; Chen W; Mou HZ; Zheng ZG
Bioanalysis; 2017 Jun; 9(12):925-935. PubMed ID: 28617069
[TBL] [Abstract][Full Text] [Related]
17. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods.
Miura M; Takahashi N
Drug Metab Pharmacokinet; 2016 Feb; 31(1):12-20. PubMed ID: 26732608
[TBL] [Abstract][Full Text] [Related]
18. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry.
Takasaki S; Tanaka M; Kikuchi M; Maekawa M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
Biomed Chromatogr; 2018 Jun; 32(6):e4184. PubMed ID: 29283445
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring.
Li G; Zhao M; Zhao L
J Pharm Biomed Anal; 2022 Apr; 212():114517. PubMed ID: 35131665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
